Lightening the burden of oral mucositis
FIRST FDA-AUTHORIZED DEVICE FOR RADIATION-INDUCED ORAL MUCOSITIS
A standardized, 10-minute daily photobiomodulation treatment designed to fit within the radiation workflow
a clinically validated approach
Meaningful improvement. Practical delivery.
Mureva was designed to address both sides of the challenge: the clinical burden of oral mucositis and the operational barriers that have limited routine PBM adoption
Reduces Severe OM
Keeps patients on treatment by lowering the severity, incidence, and duration of oral mucositis
Protects Patient Function
Helps preserve swallowing and tastes, reduces feeding tube dependence, and supports recovery
Simplifies PBM Delivery
Delivers a standardized, repeatable 10-minute daily treatment with minimal setup
randomzied, double blind, sham-controlled pivotal trial
A clear reduction in severe oral mucositis
Severe OM through two weeks post-IMRT in the FDA-indicated subgroup (n=40)
a simpler way to deliver pbm
One appointment.
One connected workflow.
Mureva uses dual, soft, and flexible intraoral mouthpieces to reach tissues most susceptible to developing OM. Treatment is delivered immedietly before radiation.
designed for routine clinical use
Built around the way cancer centers already work
Mureva can be implemented within existing ARIA workflows for ease of scheduling, charge capture, and quality assurance
01
Defined patient identification and treatment workflow
02
Implementation, training, and ongoing support
03
Coding and coverage support for treating centers